Do diabetes shots help prevent addiction problems?
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study checks if a type of diabetes medicine (GLP-1 agonists) helps prevent addiction or makes it less dangerous in veterans with diabetes.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 553 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study checks if a type of diabetes medicine (GLP-1 agonists) helps prevent addiction or makes it less dangerous in veterans with diabetes.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 553 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Publication
Related Content
Claims (6)
Starting diabetes drugs like semaglutide or liraglutide might lower the chance of developing substance use problems, and this seems to be true for people of different ages, weights, races, and types of the drug.
For US veterans with type 2 diabetes, starting a GLP-1 drug (like Ozempic) might help lower the chance of developing addiction problems—like with alcohol, drugs, or smoking—over three years compared to starting a different diabetes drug called an SGLT-2 inhibitor.
For US veterans with type 2 diabetes, taking GLP-1 drugs might help lower the chance of getting hooked on opioids over three years compared to another diabetes drug, SGLT-2 inhibitors — about 1 fewer case for every 1,000 people.
For US veterans with diabetes and substance use issues, taking GLP-1 drugs (like Ozempic) might lower their chances of ending up in the ER, being hospitalized, or dying from substance-related problems compared to those taking a different diabetes drug called SGLT-2 inhibitors.
For US veterans with type 2 diabetes and a history of substance use, starting a GLP-1 drug (like Ozempic) may lower their chances of overdosing on drugs or having suicidal thoughts compared to starting a different diabetes drug called an SGLT-2 inhibitor.